Atlas Venture's tenth fund has gained investment from university endowments and surpassed its initial cap of $250m to reach $280m.
Atlas Venture, the US-based biotechnology investment firm, has raised $280m in its tenth fund from a consortium including a number of university endowments.
The fund was oversubscribed with the original cap being $250m.
Atlas Venture is now a biotechnology company, having split from its technology team that is now operating as its own entity.
Bruce Booth, partner at Atlas Venture, said: “As fundraisings go, having done this multiple times, this was one of the smoothest and most well received fundraises…
